Lineage Cell Therapeutics, Inc.
LCTX- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000876343
No open-market purchases or sales by Lineage Cell Therapeutics, Inc. insiders were filed in the last 90 days; 131 institutions reported holding it in 13F filings for Q2 2026, worth $152.7M in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Lineage Cell Therapeutics, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 116 | 113 | −3 |
| Shares | 93.4M | 94.4M | +1.01M (+1.1%) |
| Value | $138.3M | $94.2M | −$44.1M (−31.9%) |
New holders (8)
Institutions that held Lineage Cell Therapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Corebridge Financial, Inc. | 79,480 | $79.3K | 0.00% |
| Virtu Financial LLC | 78,454 | $78.0K | 0.01% |
| Mirae Asset Global ETFs Holdings Ltd. | 66,707 | $66.5K | 0.00% |
| XTX Topco Ltd | 61,515 | $61.3K | 0.01% |
| Raymond James Financial Services Advisors, Inc. | 12,407 | $12.4K | 0.00% |
| Nisa Investment Advisors, LLC | 636 | $634 | 0.00% |
| Coppell Advisory Solutions LLC | 63 | $63 | 0.00% |
| Strategic Investment Solutions, Inc. | 44 | $45 | 0.00% |
Sold out (11)
Institutions that held Lineage Cell Therapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Wellington Management Group LLP | 467,545 | $692.0K |
| Citadel Advisors LLC | 221,220 | $327.4K |
| Jump Financial, LLC | 72,849 | $107.8K |
| American International Group, Inc. | 65,397 | $96.8K |
| Thrivent Financial for Lutherans | 15,000 | $22.0K |
| Summit Trail Advisors, LLC | 10,000 | $14.8K |
| Metropolitan Life Insurance Co | 1,666 | $2.47K |
| BFSG, LLC | 355 | $526 |
| First Manhattan Co | 94 | $139 |
| Central Trust Co | 29 | $43 |
| Covestor Ltd | 33 | $0 |